D. E. Shaw & Co., Inc. Biogen Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Biogen Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,366,207 shares of BIIB stock, worth $218 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
1,366,207
Previous 1,585,572
13.84%
Holding current value
$218 Million
Previous $217 Million
20.92%
% of portfolio
0.14%
Previous 0.22%
Shares
32 transactions
Others Institutions Holding BIIB
# of Institutions
1,066Shares Held
131MCall Options Held
2.85MPut Options Held
2.55M-
Vanguard Group Inc Valley Forge, PA17.3MShares$2.76 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15MShares$2.39 Billion1.66% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.32 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.47MShares$1.19 Billion0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.8MShares$766 Million0.11% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $23B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...